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Background
CD48, a CD2-family surface receptor expressed on
immune cells involved in various immune disorders and
cell activities has also a soluble form (sCD48) previously
found to be elevated in the serum of leukemia and
infectious diseases patients. We have demonstrated that
human peripheral blood (pb) eosinophils express mem-
brane-bound functional CD48 (mCD48) and that its
engagement activates them in vitro and in vivo in a
mouse model of asthma. In this study our hypothesis
was that the levels of both mCD48 and sCD48 are
increased in the pb of asthmatic and other allergic dis-
ease patients. Our aim was therefore to evaluate mCD48
expression on leukocytes as well as its soluble form in
the serum of asthmatic, allergic rhinitis (AR) and atopic
dermatitis (AD) patients.
Methods
Pb from asthmatic (taking only inhaled bronchodilators),
untreated AR and AD patients, and non allergic non
asthmatic controls was collected.Leukocyte fraction was
isolated and stained using Abs against CD48 andthespe-
cific markers for each cell type (T cells, B cells, neutro-
phils, monocytes, eosinophils, basophils and NK cells).
Results were analyzed by FACS. sCD48 was detected
using a specific ELISA.
Results
mCD48 expression in asthmatics was significantly
increased on eosinophils as compared with healthy
donors (p<0.001). Importantly this enhanced expression
was also found to be significant on neutrophils (p<0.015)
and monocytes (p<0.05) although at a lower extent.
Interestingly on both AR and AD derived cells, CD48
expression was decreased in comparison to the control
group. In the asthmatic group sCD48 levels were also sig-
nificantly elevated (p<0.006 and 2 folds higher) as com-
pared with the control, AR and AD groups. We also
found that sCD48 can down regulate eosinophil activa-
tion carried out by heat killed S.aureus by significantly
reducing the release of IL-8 (p<0.005).
Conclusions
Our results suggest that both the mCD48 and sCD48 may
serve as novel biomarkers for asthma. sCD48 may regula-
tethe allergic response and provide a new potential target
for the suppression of asthma. Further research must be
done in order to evaluate CD48 expression and release
throughout the course of the different forms of asthma
and its expression and function in the airways.
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